- Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire KestrelThe pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma g…Endpoints · 3mo ago↗ source
- FDA claims trial 'manipulation' tainted approval of ChemoCentryx drugThe FDA accused ChemoCentryx of manipulating the results of a pivotal clinical trial used to approve the drug Tavneos, escalating the agency's effort to pull the treatment from the market. "New i…Endpoints · 3mo ago↗ source
- Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage marketDevoted Health’s revenue and membership declined in 2025 for the first time since it launched health plans for seniors seven years ago. It’s a sign the high-profile startup, helmed by former Athe…